FEATURED

Prostate Cancer: Lower Cabazitaxel Dose Benefit

The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.

ESMO 2017 Coverage

Our complete coverage of the ESMO 2017 meeting in Madrid, Spain.

Drug Showcase: BAVENCIO (avelumab)

For merkel cell carcinoma.

Fact Sheet: Zinc and Cancer

This fact sheet is a review of study data about the relationship between zinc supplementation and cancer incidence and outcomes.

ThromboSeq for Lung Cancer Detection

The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.

Treating Older Patients With Lymphoma

As patients become older, additional factors must be considered in planning their treatment.

Confronting Extramedullary Multiple Myeloma

Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.

CDK4/6 Inhibitors in Breast Cancer Treatment

Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.

Volatile Organic Compounds and Esophageal Cancer

While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.

Understanding Blast Phase CML

A new study finds some hopeful signs of progress in understanding blast phase CML, which is typically associated with poor outcomes.

Multigene Test, Hereditary Kidney Cancers

Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.

Ask The Experts: Treating Sarcoma

Cancer Therapy Advisor interviewed 3 experts about how to best treat sarcoma.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.

ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.

Treatment Considerations for Older Patients With Lymphoma

Treatment Considerations for Older Patients With Lymphoma

As patients become older, additional factors must be considered in planning their treatment.

Paths Forward for Confronting Extramedullary Multiple Myeloma

Paths Forward for Confronting Extramedullary Multiple Myeloma

Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.

CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters